Table 2 Association of KIT expression with clinicopathological characteristics
From: Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
KIT immunohistochemical score | |||||||
|---|---|---|---|---|---|---|---|
Clinicopathological characteristics | Negative | % | Weak positive | % | Strong positive | % | P-value |
FIGO stage | |||||||
 I | 100/108 | 93 | 5/108 | 4 | 3/108 | 3 | NS; 0.39 |
 II | 56/64 | 87 | 8/64 | 13 | 0/64 | 0 | |
 III | 243/281 | 86 | 31/281 | 11 | 7/281 | 2 | |
 IV | 51/60 | 85 | 7/60 | 12 | 2/60 | 3 | |
Grade | |||||||
 1 | 186/194 | 96 | 5/194 | 3 | 3/194 | 2 | <0.0001 |
 2 | 110/132 | 83 | 20/132 | 15 | 2/132 | 2 | |
 3 | 150/182 | 82 | 25/182 | 14 | 7/182 | 4 | |
Residual tumour | |||||||
 ⩽1 cm | 201/236 | 85 | 27/236 | 11 | 8/236 | 3 | NS; 0.23 |
 >1 cm | 204/228 | 89 | 21/228 | 9 | 3/228 | 1 | |
Age | |||||||
 ⩽57 years | 229/249 | 92 | 16/249 | 6 | 4/249 | 2 | 0.0198 |
 >57 years | 224/267 | 84 | 35/267 | 13 | 8/267 | 3 | |
Tumour size | |||||||
 ⩽10 cm | 158/179 | 88 | 16/179 | 9 | 5/179 | 3 | NS; 0.83 |
 >10 cm | 287/327 | 88 | 33//327 | 10 | 7/327 | 2 | |
Ascites | |||||||
 No | 168/185 | 91 | 14/185 | 8 | 3/185 | 2 | NS; 0.29 |
 Yes | 277/322 | 86 | 37/322 | 11 | 8/322 | 2 | |
Ki-67 | |||||||
 Low (0–10%) | 253/270 | 94 | 14/270 | 5 | 3/270 | 1 | 0.0004 |
 Moderate (10–25%) | 106/130 | 82 | 19/130 | 15 | 5/130 | 4 | |
 High (>25%) | 80/101 | 79 | 17/101 | 17 | 4/101 | 4 | |
p53 | |||||||
 Normal | 192/206 | 93 | 10/206 | 5 | 4/206 | 2 | 0.0053 |
 Aberrant | 248/295 | 84 | 40/295 | 14 | 7/295 | 2 | |
